Although further development of this technology will be required to identify a safe delivery system with an improved editing efficacy, ID delivery of CRISPR or similar system for editing and/or inactivation of early driver genes of mammary carcinogenesis such as estrogen receptor α (ESR1), HOXA1, and/or EGFR may offer new opportunities for BC prevention. Here, ESR1 is linked to breast cancer.